Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : CAVALRY'S SHORT BUSTERS - MAGIC EIGHTBALLS PICKS -- Ignore unavailable to you. Want to Upgrade?

To: The Street who wrote (959)	10/4/1998 8:37:00 PM
From: CrazyTrain	Read Replies (2) \| Respond to of 1637

You are generalizing. Have you checked out G & G's past film credits? They are not new to the film industry. They have experience and know a lot of people in the business. They have made investors a lot of money in the past (Cannon $.20 to $46.00) and they have also had some problems in the past (Cannon $46 to $20). Only time will tell if they have learned to build on past successes while avoiding past failures, but all indication are that this stock will go up considerably in the next couple of years, but I think 10 cents is greatly undervalued.

To: The Street who wrote (959)	10/4/1998 11:30:00 PM
From: Cavalry	Respond to of 1637

whose turn tomorrow in the heb/asenio dueling press releases, luv'n it. did you see the spread on the heb warrants 2 5/16 x 3.... Short-Seller Asensio Accused of Manipulating Hemispherx Stock PR Newswire - October 01, 1998 02:15 Took Huge Short Position, Aggressively Publicized Misinformation to Defraud Investors NEW YORK, Oct. 1 /PRNewswire/ -- Hemispherx Biopharma (Amex: HEB) today filed lawsuits in federal court naming Asensio and Company, its agents, and certain other parties as co-conspirators in a scheme to manipulate the Hemispherx stock price and defraud Hemispherx investors. Papers that Hemispherx filed today in Eastern District Federal Court of Pennsylvania in Philadelphia allege that Asensio & Company and its co-conspirators established short positions of more than 2 million shares, then pursued an aggressive media, federal mail and Internet campaign to disseminate false and misleading information intended to drive down the Hemispherx share price and to create profits on the short sellers' positions. The suit estimates that the profits that Asensio & Company and its co-conspirators stood to make through their scheme was greater than $25 million based on their publicly stated target of driving the Hemispherx share price from its peak of about $13 per share to below $1. The lawsuit seeks to recover the $320 million in value lost by Hemispherx shareholders as a result of Asensio & Company's activities, plus punitive damages. As part of the scheme, the co-conspirators allegedly formed fraudulent brokerage clients and phantom accounts in the U.S. and in foreign countries in an attempt to mask their illegal trading activities and to evade U.S. taxes. Most of these allegedly fraudulent operations publicized different names and phone numbers for their trading operations but resided at the same Asensio & Company-related address. Since Asensio & Company launched its alleged "bear raid," a number of leading medical researchers have strongly criticized the false and misleading information that Asensio & Company has disseminated related to Hemispherx Biopharma's drug Ampligen, which is being developed for the treatment of Chronic Fatigue and Immune Deficiency Syndrome (CFIDS). For example, the law suit filed today alleges that Asensio & Company knowingly disseminated outdated figures on CFIDS incidence to present a fraudulent case to investors for the market for Hemispherx's products. According to the latest authoritative research on CFIDS incidence, an independent study published in Annals of Internal Medicine shows that the incidence of Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS) is up to 20 times greater than the numbers in outdated studies cited by Asensio & Company. The suit alleges that Asensio & Company knowingly ignored these data, which imply that between 500,000 Americans and 2,000,000 people worldwide suffer from Chronic Fatigue Syndrome, and chose instead to disseminate outdated research from the early 1990s from the Centers for Disease Control (CDC) that estimated U.S. adult incidence at only 26,000. In Congressional testimony in 1995, the Centers for Disease Control indicated that the prior CDC reports had significantly underestimated the prevalence of Chronic Fatigue Syndrome in the U.S. and that the Annals of Internal Medicine estimates were more indicative of the actual incidence. The suit alleges that Asensio & Company knowingly disseminated similarly outdated or incorrect misinformation on the efficacy and toxicity of Ampligen and on the clinical testing status of Ampligen under Food and Drug Administration regulations. Leading medical researchers from the U.S. and Europe, and clinical experts on CFIDS treatment have strongly criticized the inaccuracy and misleading nature of the reports issued by Asensio & Company and its co-conspirators. Defendant Manuel P. Asensio has been named in other securities-related lawsuits and regulatory actions. A detailed playback of the recent teleconferences in which medical experts provide corrections to the Asensio & Company misinformation campaign can be obtained by calling in the United States: 800-475-6701 and requesting access code #408590; supplemental information can be obtained by requesting access code #407448. International callers may dial 320-365-3844 and request the same access codes as U.S. dialers. SOURCE Hemispherx Biopharma, Inc. /CONTACT: William A. Carter, M.D., CEO and Chairman, 215-988-0080, Investors, Sharon Will, 212-572-0762, both of Hemispherx Biopharma; or Media, William J. Jenks of Broadgate Consultants, 212-232-2222, for Hemispherx Biopharma/ /Web site: hemispherx.com (HEB) --------------------------------------------------------------------------------

To: The Street who wrote (959)	10/5/1998 8:09:00 AM
From: Cavalry	Respond to of 1637

two separate tactics being simultaneously employed by heb, discredit and expose the motives of your enemies and then build credibility for yourself, enlist all allies and remember to seek out your enemies, enemies for they may join your fight, 10/10 5 days big presentation. possible major interviews a by product for heb Hemispherx to Report on Physical and Quality of Life Improvements in Ampligen Treatment of Chronic Fatigue PR Newswire - October 05, 1998 02:45 Hemispherx to Present at American Association for Chronic Fatigue Syndrome Research Conference NEW YORK, Oct. 5 /PRNewswire/ -- Dr. David R. Strayer of Hemispherx Biopharma, Inc. (Amex: HEB) will present a paper at the October 10, 1998, session of the American Association for Chronic Fatigue Syndrome Research Conference that reviews physical performance, cognition and quality of life improvements derived from Ampligen(R) treatment in four separate clinical studies. The clinical trials reviewed in the paper include three open-label studies and one placebo-controlled study, which together encompassed over 200 individuals meeting the Centers for Disease Control case definition for CFS. The four clinical studies utilized similar Ampligen(R) dosage levels, duration of therapy, data endpoints and collection intervals. The studies employed a series of outcome parameters that have been used to study other seriously debilitating diseases and that in the case of the controlled clinical trial were part of a protocol conducted under an Investigational New Drug application authorized by the U.S. Food and Drug Administration (FDA), with approval of the relevant institutional review boards. The outcome parameters included Karnofsky Performance Scores, exercise treadmill testing, and SCL-90-R neurocognitive function evaluation. Ampligen(R) is currently being evaluated in Phase III clinical trials and is also available under a cost-recovery program authorized by the FDA and administered in conjunction with Olsten Healthcare (NYSE: OLS). At the present time, there is no fully approved treatment specifically for CFS and to the Company's knowledge, Ampligen is the only drug authorized for Phase III clinical testing in CFS. SOURCE Hemispherx Biopharma, Inc. /CONTACT: William A. Carter, M.D., CEO and Chairman, 215-988-0080, or Investors, Sharon Will, 212-572-0762, both of Hemispherx Biopharma; or Media, William J. Jenks of Broadgate Consultants, 212-232-2222, for Hemispherx Biopharma/ /Web site: hemispherx.com (HEB OLS) --------------------------------------------------------------------------------

To: The Street who wrote (959)	10/7/1998 9:14:00 AM
From: Cavalry	Read Replies (1) \| Respond to of 1637

what's up with this street, better watch closely Great White Announces SEC Internet Newsletter Investigation Business Wire - September 24, 1998 08:44 WACO, Texas --(BUSINESS WIRE)--Sept. 24, 1998--Great White Marine & Recreation, Inc. (OTC BB: JAWS) announces that it, along with several other individuals and corporations, has received a subpoena duces tecum from the Securities and Exchange Commission (SEC) requesting the production of certain information in relation to certain Internet investment newsletters. The Company fully intends to cooperate with the SEC in their investigation, and believes the investigation is being spearheaded by an SEC task force assigned to prevent securities manipulation and fraud via the Internet.